Testing omaveloxolone for children and teens with Friedreich's Ataxia
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests a drug called omaveloxolone (BIIB141) for children and teens with Friedreich’s Ataxia. It looks at how well the drug works and how safe it is over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Friedreich's Ataxia through genetic testing.
- For children 7 to 15 years old, balance must be affected but not too severe.
- Your blood sugar levels must be well-controlled (HbA1c less than 11%).
- Any heart problems must be mild or moderate, not severe or life-threatening.
- Your heart's pumping strength must be at least 40% (normal range).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the long-term safety of omaveloxolone (BIIB141) for people with Friedreich's ataxia. You can join if you are just starting this medicine or have been taking it for less than a year.
This study follows people with Friedreich's ataxia (FA) over time to learn more about the disease. It helps researchers understand how FA affects people of all ages and may lead to better treatments.
This study follows people with Friedreich's ataxia (FA) who also have a heart condition called cardiomyopathy. By tracking how the disease progresses over time, researchers hope to better understand FA-related heart problems.
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
This study follows people with Friedreich's ataxia who took omaveloxolone during pregnancy or while breastfeeding, to check how the drug affected their health and their baby's health. It helps doctors understand the safety of this treatment for mothers and babies.
This trial tests an investigational drug called DT-216P2 in people with Friedreich's ataxia. It aims to find the right dose and see how safe and tolerable it is.
Hear when a new Friedreich Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.